Navigation Links
Volcano Corporation Announces Preliminary Fourth Quarter 2011 Revenues
Date:1/9/2012

SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral artery disease, said today it expects total revenues for the fourth quarter of 2011 will be approximately $92.7 million, bringing expected full year  2011 revenues to approximately $343.5 million.

The expectations for revenues in the fourth quarter of 2011 reflect an increase of approximately 14 percent versus revenues of $81.2 million in the fourth quarter a year ago.  Medical segment revenues increased approximately 20 percent in the fourth quarter of 2011 versus the same period a year ago. The expected revenues for all of fiscal 2011 reflect an increase of approximately 17 percent over revenues of $294.1 million in fiscal 2010.

"We are pleased with these record quarterly and annual revenues as our medical segment business continued to demonstrate solid growth—led by a strong performance in our FFR (Fractional Flow Reserve) disposable business, which increased 37 percent in the quarter versus the fourth quarter a year ago. Our IVUS (Intravascular Ultrasound) business performed to our expectations. However, due to continued softness in telecom infrastructure spending in key international geographies, we experienced a greater than anticipated reduction in Axsun Industrial segment revenues, which were approximately $1.5 million in the fourth quarter of 2011 versus revenues of $5.1 million in the fourth quarter a year ago, or a decline of approximately 70 percent," said Scott Huennekens, president and chief executive officer.

"We continue to be optimistic about the market opportunities for our current offerings—especially FFR —as well as  products in our pipeline as healthcare providers f
'/>"/>

SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
2. Upgraded ACCF/ AHA/ SCAI Guidelines Reinforce Benefits of Volcanos Precision Guided Therapy Technologies
3. Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011
4. Volcano Reports 18 Percent Increase in Total Third Quarter Revenues
5. Volcano Corporation Appoints Leslie V. Norwalk and Dr. Eric J. Topol to Board of Directors
6. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
7. Volcano Corporation Announces Presentations at Upcoming Investor Conferences
8. Volcano Reports 22 Percent Increase in Second Quarter Medical Segment Revenues and Earnings per share of $0.09
9. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
10. Volcano Corporation Presentation at William Blair Conference to be Webcast
11. Volcano Corporation Presentation at Goldman Sachs Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 Amgen (NASDAQ: ... two pivotal Phase 3, global, randomized, placebo-controlled trials ... treatment of secondary hyperparathyroidism (SHPT) in patients with ... met the primary endpoint, demonstrating that a greater ... achieved a greater than 30 percent reduction in ...
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
(Date:5/28/2015)... 2015 Zimmer Holdings, Inc. (NYSE and SIX: ... with buyers to divest in the United ... assets, Biomet Discovery® Elbow System assets and Cobalt™ bone ... Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... constructively with the Bureau of Competition Staff of the ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7The Association for the Advancement of Wound Care Educates the Public 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6
... Reportlinker.com announces that a new market research ... Triple Analysis: Lung Cancer, Lymphoma ... This triple analysis ... both Lung Cancer and Lymphoma and by ...
... 23, 2011 Applied Medical today announced that it ... Covidien) on May 17, 2011 in the U.S. District ... a recently issued Applied Medical trocar seal patent by ... Action No. CV 11-4203 VBF (AJWx). The patent is ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 2Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 3Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 4Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 5Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent 2
(Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
(Date:5/30/2015)... On Thursday, May 14, the Mesothelioma ... Dr. Evan Alley both of the University of ... series. The interview was part of the series ... Drs. Simone and Alley were interviewed by the ... they discussed the mesothelioma program at the University ...
(Date:5/30/2015)... 2015 Responding to surging demand from ... experienced OGAWA products while abroad, OGAWA-engineered massage products have ... A leader in the Asian health and wellness industry ... developer and manufacturer of health and wellness equipment. ... their products, health enthusiasts in Asia and Australia, as ...
(Date:5/30/2015)... 2015 Cyclist Barry Haarde will ... the World 2015: Piles of Miles” near San ... about hemophilia and encourage individuals to support needy ... Save One Life supports nearly 1,200 impoverished children ... through direct sponsorships, scholarships and micro-enterprise grants. Hemophilia ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The iconic ... Jones, will be hosting a new segment on Medical ... aspects of medical malpractice in the health care field. ... 2014 thousands of medical malpractice suits were filed, roughly ... 50% were settled out of court, while the remaining ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2
... Drought Tolerance, DES MOINES, Iowa, Feb. 4 ... today for a three-day project review,meeting focused on ... DD ) business Pioneer-Hi-Bred, the intent of ... and private organizations in order to,help increase farm ...
... The Beryl Companies announced today the,appointment ... president of,marketing communications. In this role, she ... branding initiatives, working closely,with sales, customer relations ... extensive background in marketing communications,research and operations ...
... by more than 78% , , MONDAY, Feb. 4 (HealthDay News) ... down, a new study shows it may also ease the ... simple sugar-and-water solution will also ease parents, fears and boost ... parents to get their children vaccinated," said study author Linda ...
... - Advocacy Group Urges Russian President Vladimir Putin to Adopt a ... ... The Movement Against Cancer, a cancer,patient advocacy group in Russia, ... inadequate access for cancer,patients in Russia to innovative and effective treatments, ...
... Calif., Feb. 4 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... announced that Jerry McMahon, Ph.D., chairman and CEO,will ... Investor Conference 2008 on,Monday, February 11, at 11:45 ... Dr. McMahon will provide a corporate overview, ...
... Medco Health,Solutions, Inc. (NYSE: MHS ) plans ... a press release before the market opens,on Tuesday, Feb. ... a conference call to review,the financial results, outlook and ... the live conference call via telephone:, Dial in: ...
Cached Medicine News:Health News:DuPont Hosts Meeting of Leading Plant Scientists to Improve World Agricultural Productivity 2Health News:Sugar Water Eases Pain of Infant Vaccinations 2Health News:Sugar Water Eases Pain of Infant Vaccinations 3Health News:Movement Against Cancer, a Cancer Patient Advocacy Group in Russia, Launches an Effort to Inform Russian Authorities and the Public About Inadequate Access of Innovative and Effective Cancer Treatments for Cancer Patients in Russia 2Health News:Poniard Pharmaceuticals Announces Upcoming Conference Participation 2Health News:Medco Announces Date for Fourth-Quarter and Full-Year 2007 Financial Results 2
... Hemoglobin Test Systems provide ... quantitative hemoglobin results with ... a large hematology analyzer. ... of either the B-Hemoglobin ...
... The HemoPoint H2 Hemoglobin Measurement ... determination of hemoglobin in arterial, venous, ... infants, and children in a professional ... number 3010-100 is indicated for use ...
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
... Self-Sampling: ,Place the ImmunoDip into ... precise amount of sample needed for,an accurate ... run to completion,in 3 minutes. , ... color bands remain stable,for at least eight ...
Medicine Products: